<DOC>
	<DOCNO>NCT02998320</DOCNO>
	<brief_summary>This study measure proportion enrol patient take uninterrupted HIV post-exposure prophylaxis Genvoya four week</brief_summary>
	<brief_title>Evaluation Compliance With Treatment Genvoya HIV Post-exposure Prophylaxis</brief_title>
	<detailed_description>This study measure proportion enrol patient take uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide ( E/C/F/TAF ) four Weeks . Elvitegravir HIV-1 integrase strand transfer inhibitor ( INSTI ) . Cobicistat selective , mechanism-based inhibitor cytochrome P450 ( CYP ) enzymes CYP3A subfamily . Emtricitabine nucleoside reverse transcriptase inhibitor ( NRTI ) nucleoside analogue Ã f 2'-dexicytidine . Tenofovir alafenamide nucleotide reverse transcriptase inhibitor ( NtRTI ) phosphonoamidate prodrug tenofovir ( 2'-deoxyadenosine monophosphate analogue ) .</detailed_description>
	<criteria>age 18 year consultation within 48 hour follow risk HIV transmission ( blood sexual contact ) indication HIV postexposure prophylaxis ( accord French guideline ) person able understand nature study person sign consent form participate study person expose HIV risk person infect HIV , whose therapeutic history justifies prescription another combination antiretroviral drug contraindication prescription Genvoy medical contraindication person infect hepatitis B virus pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>